新闻稿:Dupixent,由赛诺菲和再生元制药公司开发,成为十多年来欧盟首个针对特发性慢性荨麻疹的靶向药物
新闻稿:Dupixent,由赛诺菲和再生元制药公司开发,成为十多年来欧盟首个针对特发性慢性荨麻疹的靶向药物
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.